C4 Therapeutics, Inc. (CCCC) — Cash & Equivalents
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $74.60M | +34.4% |
| 2024 | $55.50M | -56.2% |
| 2023 | $126.59M | +325.5% |
| 2022 | $29.75M | -60.9% |
| 2021 | $76.12M | -58.1% |
| 2020 | $181.73M | +100.7% |
| 2019 | $90.55M | — |
| Fiscal Year | Cash & Equivalents | Change YoY |
|---|---|---|
| 2025 | $74.60M | +34.4% |
| 2024 | $55.50M | -56.2% |
| 2023 | $126.59M | +325.5% |
| 2022 | $29.75M | -60.9% |
| 2021 | $76.12M | -58.1% |
| 2020 | $181.73M | +100.7% |
| 2019 | $90.55M | — |